Literature DB >> 12096191

Molecular basis for the dichotomy in Plasmodium falciparum adhesion to CD36 and chondroitin sulfate A.

Benoit Gamain1, Sylvie Gratepanche, Louis H Miller, Dror I Baruch.   

Abstract

Plasmodium falciparum-infected erythrocytes adhere dichotomously to the host receptors CD36 and chondroitin sulfate A (CSA). This dichotomy is associated with parasite sequestration to microvasculature beds (CD36) or placenta (CSA), leading to site-specific pathogenesis. Both properties are mediated by members of the variant P. falciparum erythrocyte membrane protein 1 (PfEMP-1) family and reside on nonoverlapping domains of the molecule. To identify the molecular basis for the apparent dichotomy, we expressed various domains of PfEMP-1 individually or in combination and tested their binding properties. We found that the CD36-binding mode of the cysteine-rich interdomain region-1 (CIDR1) ablates the ability of the Duffy binding-like gamma domain to bind CSA. In contrast, neither a non-CD36-binding CIDR1 nor an intercellular adhesion molecule 1 binding domain had any affect on CSA binding. Our findings point out that interactions between different domains of PfEMP-1 can alter the adhesion phenotype of infected erythrocytes and provide a molecular basis for the apparent dichotomy in adhesion. We suggest that the basis for the dichotomy is structural and that mutually exclusive conformations of PfEMP-1 are involved in binding to CD36 or CSA. Furthermore, we propose a model explaining the requirement for structural dichotomy between placental and nonplacental isolates.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12096191      PMCID: PMC126617          DOI: 10.1073/pnas.152321599

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  The adhesion of Plasmodium falciparum-infected erythrocytes to chondroitin sulfate A is mediated by P. falciparum erythrocyte membrane protein 1.

Authors:  J C Reeder; A F Cowman; K M Davern; J G Beeson; J K Thompson; S J Rogerson; G V Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

2.  Maternal antibodies block malaria.

Authors:  M Fried; F Nosten; A Brockman; B J Brabin; P E Duffy
Journal:  Nature       Date:  1998-10-29       Impact factor: 49.962

Review 3.  New insights into the epidemiology of malaria relevant for disease control.

Authors:  R W Snow; K Marsh
Journal:  Br Med Bull       Date:  1998       Impact factor: 4.291

4.  Identification of a region of PfEMP1 that mediates adherence of Plasmodium falciparum infected erythrocytes to CD36: conserved function with variant sequence.

Authors:  D I Baruch; X C Ma; H B Singh; X Bi; B L Pasloske; R J Howard
Journal:  Blood       Date:  1997-11-01       Impact factor: 22.113

5.  Adhesion of Plasmodium falciparum-infected erythrocytes to hyaluronic acid in placental malaria.

Authors:  J G Beeson; S J Rogerson; B M Cooke; J C Reeder; W Chai; A M Lawson; M E Molyneux; G V Brown
Journal:  Nat Med       Date:  2000-01       Impact factor: 53.440

6.  Plasmodium falciparum isolates from infected pregnant women and children are associated with distinct adhesive and antigenic properties.

Authors:  J G Beeson; G V Brown; M E Molyneux; C Mhango; F Dzinjalamala; S J Rogerson
Journal:  J Infect Dis       Date:  1999-08       Impact factor: 5.226

7.  Plasmodium falciparum domain mediating adhesion to chondroitin sulfate A: a receptor for human placental infection.

Authors:  P A Buffet; B Gamain; C Scheidig; D Baruch; J D Smith; R Hernandez-Rivas; B Pouvelle; S Oishi; N Fujii; T Fusai; D Parzy; L H Miller; J Gysin; A Scherf
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

8.  Antigenic variation in malaria: in situ switching, relaxed and mutually exclusive transcription of var genes during intra-erythrocytic development in Plasmodium falciparum.

Authors:  A Scherf; R Hernandez-Rivas; P Buffet; E Bottius; C Benatar; B Pouvelle; J Gysin; M Lanzer
Journal:  EMBO J       Date:  1998-09-15       Impact factor: 11.598

9.  Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria.

Authors:  P C Bull; B S Lowe; M Kortok; C S Molyneux; C I Newbold; K Marsh
Journal:  Nat Med       Date:  1998-03       Impact factor: 53.440

10.  Analysis of adhesive domains from the A4VAR Plasmodium falciparum erythrocyte membrane protein-1 identifies a CD36 binding domain.

Authors:  J D Smith; S Kyes; A G Craig; T Fagan; D Hudson-Taylor; L H Miller; D I Baruch; C I Newbold
Journal:  Mol Biochem Parasitol       Date:  1998-11-30       Impact factor: 1.759

View more
  18 in total

1.  Regioselectively modified sulfated cellulose as prospective drug for treatment of malaria tropica.

Authors:  Reinhard Schwartz-Albiez; Yvonne Adams; Claus-W von der Lieth; Petra Mischnick; Katherine T Andrews; Michael Kirschfink
Journal:  Glycoconj J       Date:  2007-01       Impact factor: 2.916

2.  Chondroitin sulfate proteoglycan expression and binding of Plasmodium falciparum-infected erythrocytes in the human placenta during pregnancy.

Authors:  Sean T Agbor-Enoh; Rajeshwara N Achur; Manojkumar Valiyaveettil; Rose Leke; Diane W Taylor; D Channe Gowda
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

3.  Full-length extracellular region of the var2CSA variant of PfEMP1 is required for specific, high-affinity binding to CSA.

Authors:  Anand Srivastava; Stéphane Gangnard; Adam Round; Sébastien Dechavanne; Alexandre Juillerat; Bertrand Raynal; Grazyna Faure; Bruno Baron; Stéphanie Ramboarina; Saurabh Kumar Singh; Hassan Belrhali; Patrick England; Anita Lewit-Bentley; Artur Scherf; Graham A Bentley; Benoît Gamain
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-01       Impact factor: 11.205

Review 4.  Variant surface antigens of Plasmodium falciparum and their roles in severe malaria.

Authors:  Mats Wahlgren; Suchi Goel; Reetesh R Akhouri
Journal:  Nat Rev Microbiol       Date:  2017-06-12       Impact factor: 60.633

5.  The C-terminal segment of the cysteine-rich interdomain of Plasmodium falciparum erythrocyte membrane protein 1 determines CD36 binding and elicits antibodies that inhibit adhesion of parasite-infected erythrocytes.

Authors:  Min Mo; Hooi Chen Lee; Masayo Kotaka; Makhtar Niang; Xiaohong Gao; Jayasree Kaveri Iyer; Julien Lescar; Peter Preiser
Journal:  Infect Immun       Date:  2008-02-25       Impact factor: 3.441

6.  Binding affinity of Plasmodium falciparum-infected erythrocytes from infected placentas and laboratory selected strains to chondroitin 4-sulfate.

Authors:  Rajeshwara N Achur; Arivalagan Muthusamy; SubbaRao V Madhunapantula; D Channe Gowda
Journal:  Mol Biochem Parasitol       Date:  2008-02-14       Impact factor: 1.759

7.  Induction of crossreactive antibodies against the Plasmodium falciparum variant protein.

Authors:  Sylvie Gratepanche; Benoit Gamain; Joseph D Smith; Bridget A Robinson; Allan Saul; Louis H Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-20       Impact factor: 11.205

8.  DNA immunization with the cysteine-rich interdomain region 1 of the Plasmodium falciparum variant antigen elicits limited cross-reactive antibody responses.

Authors:  Dror I Baruch; Benoit Gamain; Louis H Miller
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

9.  Developmental stage- and cell cycle number-dependent changes in characteristics of Plasmodium falciparum-infected erythrocyte adherence to placental chondroitin-4-sulfate proteoglycan.

Authors:  Subbarao V Madhunapantula; Rajeshwara N Achur; D Channe Gowda
Journal:  Infect Immun       Date:  2007-06-25       Impact factor: 3.441

10.  Six genes are preferentially transcribed by the circulating and sequestered forms of Plasmodium falciparum parasites that infect pregnant women.

Authors:  Susan E Francis; Vladislav A Malkov; Andrew V Oleinikov; Eddie Rossnagle; Jason P Wendler; Theonest K Mutabingwa; Michal Fried; Patrick E Duffy
Journal:  Infect Immun       Date:  2007-08-13       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.